Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Pacira BioSciences Community
NasdaqGS:PCRX Community
1
Narratives
written by author
0
Comments
on narratives written by author
16
Fair Values set
on narratives written by author
Create a narrative
Pacira BioSciences
Popular
Undervalued
Overvalued
Community Investing Ideas
Pacira BioSciences
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
New Reimbursement Codes And Acquisitions Will Expand Patient Access And Product Pipeline
Key Takeaways Introduction of product-specific reimbursement codes and DTC marketing initiatives are expected to expand patient access and increase product revenue. Execution of growth strategies and acquisition for new product development holds potential for significant revenue and profitability increases.
View narrative
US$36.00
FV
30.1% undervalued
intrinsic discount
10.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
8 days ago
author updated this narrative
Your Valuation for
PCRX
PCRX
Pacira BioSciences
Your Fair Value
US$
Current Price
US$25.18
38.1% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-100m
1b
2015
2018
2021
2024
2025
2027
2030
Revenue US$1.1b
Earnings US$161.7m
Advanced
Set Fair Value